PROVIDENCE – Rhode Island Hospital and The Miriam Hospital are both participating in an international clinical trial to test the effectiveness of a new vaccine for patients with non-small-cell lung cancer, the most common type of lung cancer.
In 2010, an estimated 222,000 patients in the U.S. will be diagnosed with lung cancer, with between 80 to 90 percent of cases being non-small cell.
ISO 9001:2026: A Practical Opportunity to Build for What’s Next
For Rhode Island manufacturers, ISO 9001 has been much more than a certificate on the…
Learn More
The Rhode Island component of the study is being led by a team including thoracic surgeon Thomas Ng, radiation oncologist Thomas Dipetrillo and medical oncologists Angela Plette and Humera Khurshid.
The two-year clinical trial, sponsored by GlaxoSmithKline, will examine the potential of the vaccine to stimulate the immune system to respond to the patient’s own cancer cells, with the hope of extending survival rates, improving quality of life and reducing the chance for tumor recurrence.
During the trial, participants will receive a series of 13 doses of the vaccine or a placebo, with follow-up visits and monitoring.
Patients are currently being recruited to participate in the study. They must be 18 years of age or older, have been diagnosed with non-small-cell lung cancer, undergone surgical resection of the lung cancer and show no evidence of disease following surgery.
